ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model-Reference-Cited by-同舟云学术

ADAMTS13 autoantibodies cloned from patients with acquired thrombotic thrombocytopenic purpura: 2. Pathogenicity in an animal model

Published:2016-04-04 Issue:7 Volume:56 Page:1775-1785
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Ostertag Eric M.¹²,Bdeir Khalil¹,Kacir Stephen¹,Thiboutot Michelle¹,Gulendran Gayathri¹,Yunk Lenka¹,Hayes Vincent M.³,Motto David G.⁴,Poncz Mortimer³,Zheng X. Long⁵⁶,Cines Douglas B.¹,Siegel Don L.¹

Affiliation:

1. Department of Pathology & Laboratory Medicine; Perelman School of Medicine at the University of Pennsylvania; Philadelphia Pennsylvania

2. Poseida Therapeutics, Inc; San Diego California

3. Division of Hematology; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

4. Bloodworks Northwest Research Institute; Seattle Washington

5. Department of Pathology & Laboratory Medicine; Children's Hospital of Philadelphia; Philadelphia Pennsylvania

6. Division of Laboratory Medicine; Department of Pathology; The University of Alabama at Birmingham; Birmingham Alabama

Funder

National Institutes of Health

National Blood Foundation

Answering TTP Foundation

University of Pennsylvania

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.13583/fullpdf

Reference44 articles.

1. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura;Tsai;N Engl J Med,1998

2. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura;Peyvandi;Br J Haematol,2004

3. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura;Zheng;Blood,2004

4. Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo;Shelat;J Thromb Haemost,2006

5. Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity;Ferrari;Blood,2007

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of Inhibition of Human Monoclonal Antibodies in Immune Thrombotic Thrombocytopenic Purpura;Blood;2023-04-06

2. Hydrodynamic Delivery: Characteristics, Applications, and Technological Advances;Pharmaceutics;2023-03-31

3. ADAMTS13 conformations and mechanism of inhibition in immune thrombotic thrombocytopenic purpura;Journal of Thrombosis and Haemostasis;2022-10

4. Distinct impact of IgG subclass on autoantibody pathogenicity in different IgG4-mediated diseases;eLife;2022-08-03

5. Naturally Occurring Anti-Idiotypic Antibodies Portray a Largely Private Repertoire in Immune-Mediated Thrombotic Thrombocytopenic Purpura;The Journal of Immunology;2022-06-01